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PHARMACY 421 - MEDICINAL CHEMISTRY I AUTUMN SEMESTER, 2000
INSTRUCTORS: David Freeman, Office: SB 308 Office Phone: 243-4772 Home Phone: 728-6
 551
E-m
 ail: dfreeman@selwav.umt.edu Internet Site: www.umt.edu/pharmacv
Chuck Thompson, Office: SB 383 Office Phone: 243-4643
E-m
 ail: cmthomp@selwav.umt.edu Internet Site: www.umt.edu/medchem
EXAMS AND GRADING:
First Exam: Tuesday, Oct. 3 ........................50 points
Second Exam: Thursday, Nov. 2  ............. 70 points
Third Exam: Tuesday, Dec. 12 .........................80 points
Final Exam: ...............100 points
10 Point Quizzes: Best 5 out of 6 scores 50 points
Total Points: 350 90-100% = A 80-89 % = B 70-79 % = C 65-69 % = 
­D
* All EXAMS are comprehensive
* All exams and quizzes must be taken at scheduled times
* Instructor must be informed BEFORE missing a scheduled exam period
and must be based on GOOD REASONS
* Missed exam periods must be made up within 2 days
* No make up quizzes
STUDENT PERFORMANCE OBJECTIVES:
1) Identify organic functional groups and know their polar/lipophilic and acid/base properties
2) Know the relationships between organic functional groups and biological activity
3) Know the possible modes of metabolism in the body for organic functional groups
4) Know the chemical structures of important neurotransmitters or hormones and the biochemical 
pathways for their syntheses and metabolism
5) Know the major biochemical events triggered by the activation of receptors important for drug action
6) Given the chemical structure of a drug, know its pharmacologic or therapeutic class
7) Given the chemical structure of a drug, khow important chemical features (acid/base or lipophilic 
properties, chemical groups affecting absorption, distribution, or metabolism, chemical groups 
affecting potency or receptor interaction, chemical groups affecting storage or formulation)
that contribute to the drug's pharmacological activity
8) Given the chemical structure of a drug, know important chemical changes that will predictably 
alter the pharmacological properties (potency, duration of action, etc.) of the drug
9) Given the chemical structure of a drug, know the important biological receptors it interacts 
with and the biochemical events produced by these interactions
10) Given the common or generic name of a drug, know its pharmacologic or therapeutic class, 
some of its important chemical properties (structural skeleton or chemical class, acid/base, etc.), 
the receptors it interacts with and the biochemical events produced by these interactions
TEXTBOOK: Goodman & Gilman's "The Pharmacological Basis of Therapeutics", Ninth Edition
Reading 
In Text
I. Physicochemical Properties of Drugs Related to Pharmacological Activity and Metabolism
A. Organic Functional Groups in Medicinal Chemistry 
3-4 1 ■ Physicochemical Properties
11-16 2. Metabolic Fate
B. Acid/Base Review
1. Equilibrium 
3-4 2. pKa values
C. Quantitative Structure-Activity Relationships
1. Concept of Linear Free Energy Relationships
2. Hydrophobicity and Log P values
3. Electronic Effects and Sigma values
D. Problem Solving in Medicinal Chemistry
II. Biochemical Processes Affecting Drugs and Pharmacological Activity
A. Processes Affecting Drug Distribution 
9-11 1. Non-specific binding sites and plasma protein binding
11-16 2. Biotransformation reactions (metabolism)
Reading
In Text
8. Processes Affecting Drug Action at the Active Site 
31-33 . 1. Structural families of receptors
39-40 2. Binding events initiating the pharmacological response
a. Occupancy and conformational changes of receptor
b. Agonist vs. antagonist events
34-37 3. Events propagating and amplifying pharmacological response
4. Events terminating the pharmacological response
III. Processes and Overview of Drugs Affecting Cholinergic Receptors
A, Biochemical Events at the Cholinergic Synapse 
115-119 1. Synthesis and metabolism of acetylcholine
2. Muscarinic and nicotinic receptors
3. Processes following receptor activation
B. Overview on Cholinergic Drugs
IV. Muscarinic Receptor Agonists
141-143 A. Chemistry of Acetylcholine
1. Important functional groups
2. Conformations of acetylcholine
B. SAR and Chemistry of Selected Agonists
* METHACHOLINE CARBACHOL BETHANECHOL PILOCARPINE GEVIMELINE *
V. Cholinergic Antagonists 
148-150 A. Muscarinic Blocking Agents
1. Natural product and model agent -
 atropine
2. SAR and chemistry of selected antimuscarinic agents
a. Tertiary agiines
* ATROPINE SCOPOLAMINE HOMATROPINE 
'DICYCLOMINE CYCLOPENTOLATE*
b. Quaternary amines
* GLYCOPYRROLATE METHANTHELINE *
'PROPANTHELINE IPRATROPIUM *
VI. Anticholinesterase Agents
161-164 A. Mechanism of Acetylcholine Hydrolysis
1. Individual steps involved in hydrolysis
2. Rates of reaction steps
162-165 B. Mechanisms of Cholinesterase Inhibition
1. Competitive binding at active site
2. Covalent binding at active site 
165-167 C. SAR and Chemistry of Cholinesterase inhibitors
1. Natural product and model agent * PHYSOSTIGMINE '
2. Competitive inhibitors * EDROPHONIUM *
3. Carbamates - "reversible" inhibitors
'NEOSTIGMINE PYRIDOSTIGMINE'
4. Organophosphates - "irreversible" inhibitors
* ECHOTHIOPHATE ISOFLUROPHATE PARATHION MALATHION * 
170-171 D. Reactivation of Inhibited Cholinesterase * PRALIDOXIME *
VII. Agents Acting At Nicotinic Receptors
177-178 A. Properties of the Nicotinic Cholinergic Receptor
178-182 B. Neuromuscular blocking agents
1. Natural product and model agent * TUBOCURARINE *
2. Competitive agents '  MIVACURIUM ATRACURIUM PANCURONIUM *
3. Depolarizing agents ‘ DECAMETHONIUM SUCCINYLCHOLINE * 
193-195 C. Ganglionic blocking agents
* HEXAMETHONIUM TRIMETHAPHAN MECAMYLAMINE *
Reading
In Text
VIII. Processes and Overview of Drugs Affecting Adrenergic Receptors
A. Biochemical Events at the Adrenergic Synapse
118-123 1 • Synthesis and storage of norepinephrine
123-1
 24 2. Termination and metabolism of catecholamines
124-1
 27 3. Alpha and beta receptors and subtypes
127-1
 30 4. Processes following receptor activation
B. Overview on Adrenergic Drugs
IX. Adrenergic Receptor Agonists
A. Chemistry of Norepinephrine and Epinephrine
1. Oxidative and acid/base properties
2. Stereochemistry
200-203 B. SAR and Chemistry of Selected Agonists
1. Differentiating alpha and beta activity
2. Decreasing metabolism
3. Peripheral vs. CNS effects
4. Direct and indirect effects
* DOPAMINE ISOPROTERENOL TERBUTALINE METAPROTERENOL *
* ALBUTEROL SALMETEROL EPHEDRINE PHENYLPROPANOLAMINE *
* RITODRINE CLONIDINE AMPHETAMINE TETRAHYDROZOLINE *
* METHYLPHENIDATE DOBUTAMINE METHOXAMINE PHENYLEPHRINE 
•PHENTERMINE FENFLURAMINE METHYLPHENlDATE PEMOLINE COCAINE*
203-204 5. Physiological and biochemical mechanisms
X. Adrenergic Receptor Antagonists
225-227 A. Alpha Blocking Agents v
227-228 1. Chemistry of haloaikylamines * PHENOXYBENZAMINE *
228-229 2. Chemistry of imidazolines * PHENTOLAMiNE TOLAZOLINE*
229-230 3. Selective blockers * PRAZOSIN TERAZOSIN DOXAZOSIN*
232-233 B. Beta Blocking Agents
237 1. Nonselective blockers
* PROPRANOLOL NADOLOL TIMOLOL PINDOLOL CARTEOLOL*
238-239 2. Selective blockers * METOPROLOL ATENOLOL ACEBUTOLOL ESMOLOL *
3. Blockers with intrinsic sympathomimetic activity {ISA blockers)
4. Combined alpha and beta blocker * LABETALOL *
XI. Antihistamines and Other Agents
581-586 A. Biochemistry of Histamine Synthesis, Metabolism, and Receptors
586-592 B. Hi receptor antagonists
* DIPHENHYDRAMINE CHLORPHENIRAMINE CYCUZINE PYRILAMINE *
* PROMETHAZINE TERFENADINE LORATADINE ASTEMtZOLE FEXOFENADINE * 
901-906 C. H2 receptor blocking agents
* CIMETIDINE RANITIDINE FAMOTIDINE NIZATIDINE*
907-909 D. Inhibitors of H+/K+ ATPase
‘ OMEPRAZOLE LANSOPRAZOLE RABEPRAZOLE PANTOPRAZOLE*
667-669 E. Inhibitors of histamine release
* CROMOLYN SODIUM NEDOCROMIL SODIUM *
XII. Local and General Anesthetics
331-332 A. SAR and Chemistry of Local Anesthetic Agents
1. Natural product and model compound * COCAINE *
2. Synthetic esters and amides
•PROCAINE LIDOCAINE TETRACAINE ETIDOCAINE *
* BENZOCAINE PRAMOXINE *
332-333 B. Nonspecific and Specific Effects on Neural Membranes
333-336 C. Factors Affecting Activity of Agents
337-338 D. Adverse effects and metabolism
E. Structure and Chemical Properties of General Anesthetic Agents
* DIETHYL ETHER NITROUS OXIDE HALOTHANE ISOFLURANE *
Reading
In Text
XIII. Sedative/Hypnotic Agents
A. Benzodiazepines
362-364 1. Structure, Chemical Properties, and SAR
364-367 2. Biochemical effects
* DIAZEPAM CHLORD1AZEPOXIDE FLURAZEPAM OXAZEPAM * 
‘ TRIAZOLAM MIDAZOLAM LORAZEPAM ZOLPIDEM*
373-377 B. Barbiturates
1. Chemical properties and SAR of agents
2. Biochemical effects
* PHENOBARBITAL PENTOBARBITAL SECOBARBITAL*
* BUTABARBITAL THIOPENTAL *
381 C. Non-barbiturates * CHLORAL HYDRATE *
XIV. Opioid Analgesic Agents
521-527 A. Biochemistry of Endorphins, Enkephalins, and Their Receptors
B. Natural Product and Model Agent * MORPHINE*
527-530 C. SAR, Stereochemistry, and Chemical Properties
1. Chemical features of morphine
2 N-Substituents producing agonist, partial agonist, or antagonist effects
3. Synthetic agents
‘ HEROIN HYDROMORPHONE CODEINE MEPERIDINE LEVORPHANOL* 
‘ BUTORPHANOL METHADONE FENTANYL PENTAZOCINE ETORPHINE * 
* NALOXONE NALTREXONE DEXTROMETHORPHAN *
XV. Antineoplastic Agents v
1233-1238 A. Chemistry and Mechanisms of Action for Alkylating and Cross-linking Agents /
* MECHLORETHAMINE CHLORAMBUCIL CYCLOPHOSPHAMIDE IPOSFAMIDE * \ .
* BUSULFAN CARMUSTINE LOMUSTINE DACARBAZINE PROCARBAZINE*
1269-1272 * CISPLATIN CARBOPLATIN*
B. Mechanisms of Action for Antimetabolite Agents
1243-1247 * METHOTREXATE LEUCOVORIN FLUOROURACIL FLOXURIDINE *
1252-1257 * CYTARAB1NE GEMCITABINE CLADRIBINE PENTOSTATlN MERCAPTOPURINE *
C. Mechanisms of Action for Natural Products and Miscellaneous Agents
1258-1262 * VINCRISTINE VINBLASTINE PACLITAXEL ETGPOSIDE *
1268, 1271 * ASPARAGINASE HYDROXYUREA*
D. Mechanisms of Action for Antibiotic Type Agents
1263-1267 * DAUNORUBICIN DOXORUBICIN IDARUBICIN BLEOMYCIN*
1268 * MITOXANTRONE MITOMYCIN DACTJNOMYCIN*
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